Clinical Outcome of Ixazomib (NINLARO®) Based Regimens in Chinese Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen in Clinical Setting of Real World : An Open-Label, Single-Arm, Multicenter, Observation Study
Latest Information Update: 26 May 2023
At a glance
- Drugs Ixazomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms MODIFY
- Sponsors Takeda
- 04 Dec 2022 Trial design published in the Advances in Therapy
- 26 Nov 2021 Status changed from not yet recruiting to recruiting.
- 25 Aug 2021 New trial record